Using multivariate analysis, high levels of CD56 expression were found to significantly affect the OS of de novo non-M3 AML patients adversely, with a hazard ratio (HR) of 2.719 (P = 0.006), in line with the consensus that accepting BMT is an optimistic factor with an HR of 0.098 (P = 0.023), and poor ELN risk is an adverse prognostic factor with an HR of 3.874 (P < 0.001). Here, NCAM1 is linked to acute myeloid leukemia.